Key result
Short-term trimetazidine significantly improved left ventricular ejection fraction (P=0.007) and systolic wall thickening (P<0.05) compared to placebo in diabetic ischemic cardiomyopathy.
Why the study?
Does trimetazidine improve myocardial perfusion and left ventricular systolic function in patients with type 2 diabetes and ischemic cardiomyopathy?
Population
34 clinically stable patients with type 2 diabetes mellitus and documented multivessel coronary artery…
Comparison
Trimetazidine 20 mg three times daily for 3 months vs Placebo for 3 months
Design
RCT, Patients were randomized into two groups
Follow-up
3 months
Authors
Loading...
May support TMZ in diabetic ischemic cardiomyopathy; leaves open confirmation in randomized trials.
RCT (n=34)
Randomized
Does trimetazidine improve myocardial perfusion and left ventricular systolic function in patients with type 2 diabetes and ischemic cardiomyopathy?
p-value: p=0.007
Short-term trimetazidine improves left ventricular systolic function and exercise capacity in patients with type 2 diabetes and ischemic cardiomyopathy, despite no change in myocardial perfusion.
Belardinelli et al. (2008) conducted an RCT in Type 2 diabetes mellitus with ischemic cardiomyopathy (n=34). Trimetazidine vs. Placebo was evaluated on Left ventricular ejection fraction (p=0.007). Short-term trimetazidine significantly improved left ventricular ejection fraction (P=0.007) and systolic wall thickening (P<0.05) compared to placebo in diabetic ischemic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: